TOKYO--(BUSINESS WIRE)--PHC Corporation’s Biomedical Division (headquarters: Minato-ku, Tokyo, President: Nobuaki Nakamura, hereafter Biomedical Division), provider of PHCbi-branded products including ultra-low temperature freezers and CO2 incubators, announced today that a new subsidiary in Indonesia established in March for sales and servicing of equipment including area in life science has today commenced business activities, after completing relevant requirements such as securing a distribution license for medical devices.

东京-（商业线）-PHC公司的生物医学部门（总部：东京都Minato-ku，总裁：Nobuaki Nakamura，以下简称生物医学部门），PHCbi品牌产品供应商，包括超低温冰箱和CO2培养箱，今天宣布，印度尼西亚3月份成立的一家新子公司负责销售和服务包括生命科学领域在内的设备，在完成诸如获得医疗设备分销许可等相关要求后，现已开始开展业务活动。

The company, PT PHC Sales Indonesia (hereafter PHCSI), a subsidiary of SciMed (Asia) Pte Ltd (headquarters: Singapore, hereafter SciMed) which is in turn wholly owned by PHC Holdings Corporation (hereafter PHCHD), will further reinforce the foundation and facilitate growth of the Biomedical Division’s life science business in Indonesia..

该公司PT PHC销售印度尼西亚（以下简称PHCSI），SciMed（亚洲）Pte Ltd（总部：新加坡，以下简称SciMed）的子公司，后者又由PHC Holdings Corporation（以下简称PHCHD）合资，将进一步加强该基金会并促进生物医学部门在印度尼西亚的生命科学业务的发展。。

The life science equipment market for the Asia Pacific region is poised for solid growth, reflecting an increase in R&D investment for biopharmaceuticals and growth in new medical institutions. Particularly in Indonesia, where the national health insurance system supports the world’s fourth-largest population of approx.

亚太地区的生命科学设备市场有望强劲增长，反映了生物制药研发投资的增加和新医疗机构的增长。特别是在印度尼西亚，国家医疗保险体系支持世界第四大人口。

279 million*1, high market growth is forecast for the future due to a rise in lifestyle-related diseases such as diabetes and cancer as well as consumer demand for improved medical services..

2.79亿*1，由于糖尿病和癌症等生活方式相关疾病的增加以及消费者对改善医疗服务的需求，预计未来市场将大幅增长。。

The Biomedical Division, through fellow PHCHD subsidiary SciMed in Singapore, is already conducting sales and service for life science equipment in Southeast Asia, India and Oceania. PT PHC Indonesia (hereafter PHCI), a manufacturing subsidiary of PHCHD, also operates in the region as a secondary manufacturing base after Japan to respond to global demand for high-quality products such as biomedical freezers, pharmaceutical refrigerators, and CO2 incubators..

生物医学部门通过新加坡PHCHD附属SciMed研究员，已经在东南亚，印度和大洋洲开展生命科学设备的销售和服务。PT PHC印度尼西亚（以下简称PHCI）是PHCHD的制造子公司，在日本之后也在该地区作为二级制造基地运营，以应对全球对生物医学冷冻机，药柜和二氧化碳培养箱等高质量产品的需求。。

Now the establishment of PHCSI will allow the Biomedical Division to create a sales and service platform in Indonesia, reaching potential new customers and expanding its distributor network while strengthening customer service. By closely monitoring this market, the Biomedical Division will be better positioned to fulfill customer needs, develop new business opportunities in Indonesia, and accelerate business growth by utilizing its high manufacturing capabilities to deliver high-quality products..

现在，PHCSI的建立将使生物医学部门能够在印度尼西亚建立销售和服务平台，接触潜在的新客户并扩展其分销商网络，同时加强客户服务。通过密切监控这个市场，生物医学部门将能够更好地满足客户需求，在印度尼西亚开发新的商业机会，并通过利用其高制造能力提供高质量的产品来加速业务增长。。

Nobuaki Nakamura, President, Representative Director of PHC Corporation and Director of the Biomedical Division said, “I am pleased that our new company in Indonesia has started full-scale operations today. In order to reinforce the Biomedical Division’s life science business foundations in Southeast Asia with high market growth potential, we’ve put our best efforts into establishing a new sales company fully prepared for business launch in Indonesia, following our 100% ownership acquisition of SciMed*2 this past June.

PHC公司代表董事兼生物医学部主任Nobuaki Nakamura总裁说， “我很高兴我们在印度尼西亚的新公司今天已经开始全面运营。为了加强东南亚生物医学部门具有高市场增长潜力的生命科学业务基础，我们尽最大努力建立新的销售公司在我们100%收购SciMed*2 th之后，为在印度尼西亚开展业务做好充分准备是六月过去的。

In the coming years, PHCSI along with SciMed will be well-positioned to function as an important operating location in Asia for PHC Group and further expand existing business in Indonesia and promote full-scale entry into advanced medical treatments such as cell and gene therapies. And with PHC Group’s cross-business synergies, we will contribute to further business growth and empower researchers to develop advanced therapies to help build a future of better healthcare.”.

未来几年，PHCSI和SciMed将成为PHC集团在亚洲的重要运营地点，并进一步扩大印度尼西亚现有业务，促进全面进入细胞和基因治疗等先进医疗领域。通过PHC集团的跨业务协同作用，我们将为进一步的业务发展做出贡献，并授权研究人员开发先进的疗法，以帮助建立更好的医疗保健未来“。

Overview of PT PHC Sales Indonesia

PT PHC销售印度尼西亚概述

Company Name: PT PHC Sales Indonesia

公司名称：PT PHC销售印度尼西亚

Business: Sales and servicing support of equipment including area in life science

业务：包括生命科学领域在内的设备销售和维修支持

Established: March 3, 2023

成立日期：2023年3月3日

Address: Jakarta, Indonesia

地址：印度尼西亚雅加达

Representative: Sachihiko Kataoka

代表：Sachihiko Kataoka

Capital: 10 Billion IDR (Approx. 95 million JPY) *3

资本：100亿IDR（约9500万JPY）*3

(*1) Japan External Trade Organization www.jetro.go.jp/world/asia/idn/

（*1）日本对外贸易组织www.jetro.go.jp/world/asia/idn/

(*2) www.phchd.com/global/news/2023/0615

(*2) www.phchd.com/global/news/2023/0615

(*3) Calculated with 1IDR = 0.0095JPY

（*3）以1IDR=0.0095JPY计算

About Biomedical Division of PHC Corporation

PHC公司生物医学部

Established in 1969, PHC Corporation is a Japanese subsidiary of PHC Holdings Corporation (TOKYO: 6523), a global healthcare company that develops, manufactures, sells and services solutions across diabetes management, healthcare solutions, life sciences and diagnostics. The Biomedical Division supports the life sciences industry helping scientists and researchers in around 110 countries and regions through its laboratory equipment and services including PHCbi branded CO2 incubators and ultra-low temperature freezers..

PHC Corporation成立于1969年，是PHC Holdings Corporation（东京：6523）的日本子公司，PHC Holdings Corporation是一家全球医疗保健公司，负责开发，制造，销售和服务糖尿病管理，医疗保健解决方案，生命科学和诊断方面的解决方案。生物医学部门通过其实验室设备和服务，包括PHCbi品牌的二氧化碳培养箱和超低温冷冻机，支持生命科学行业帮助110个国家和地区的科学家和研究人员。。

www.phchd.com/apac/biomedical

www.phchd.com/apac/biomedical

About PHC Holdings Corporation

关于PHC Holdings Corporation

PHC Holdings Corporation (TOKYO: 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Wemex Corporation, and Mediford Corporation.

PHC Holdings Corporation（东京：6523）是一家全球医疗保健公司，其使命是通过具有积极影响和改善人们生活的医疗保健解决方案为社会健康做出贡献。其子公司包括PHC公司，Ascensia Diabetes Care Holdings AG，Epredia Holdings Ltd.，LSI Medience Corporation，Wemex Corporation和Mediford Corporation。

Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, diagnostics and life sciences. The consolidated net sales in FY2022 were JPY 356.4 billion with global distribution of products and services in more than 125 countries and regions.

这些公司共同开发，制造，销售和服务解决方案，涵盖糖尿病管理，医疗保健解决方案，诊断和生命科学。2022财年的合并净销售额为3564亿先令，全球产品和服务分布在125多个国家和地区。

PHC Group is a collective term referring to PHC Holdings Corporation and its subsidiaries..

PHC集团是指PHC控股公司及其子公司的统称。。

www.phchd.com

www.phchd.com

About SciMed (Asia) Pte Ltd

关于SciMed（亚洲）有限公司

SciMed (Asia) Pte Ltd, headquartered in Singapore, is an established and leading provider of products and services for biomedical, life sciences, healthcare, drug discovery, pharmaceutical, laboratories, industrial tests, and agricultural markets. SciMed has become the wholly owned subsidiary of PHC Holdings Corporation in 2023, advancing sales and marketing in life sciences business across Southeast Asia, India, and Oceania..

SciMed（亚洲）有限公司总部设在新加坡，是生物医学，生命科学，医疗保健，药物发现，制药，实验室，工业测试和农业市场的成熟和领先的产品和服务提供商。SciMed已于2023年成为PHC Holdings Corporation的合资子公司，推动东南亚，印度和大洋洲生命科学业务的销售和营销。。

https://scimed.com.sg/about-scimed/

https://scimed.com.sg/about-scimed/